Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Postoperative Pain Management in Hip Arthroplasty: A Prospective, Randomized, Single Blind, Active Controlled Study

What this Trial Is About

Researchers are studying the pain-relief effects of liposomal bupivacaine plus bupivacaine compared to ropivacaine for Pericapsular Nerve Group (PENG) block in patients undergoing hip replacement surgery. The trial aims to determine if liposomal bupivacaine plus bupivacaine provides better pain control, longer duration of relief, reduced opioid use, and higher patient satisfaction while monitoring safety. This is a randomized, double-blind, active-controlled Phase 4 study sponsored by Huazhong University of Science and Technology. Participants receive either liposomal bupivacaine plus bupivacaine or ropivacaine as a local anesthetic for the PENG block under ultrasound guidance. All undergo hip replacement surgery under spinal anesthesia. The study compares analgesic efficacy, pain relief duration, opioid consumption, and safety profiles between the two interventions within 72 hours after surgery. During the trial, pain intensity, opioid use, and complications are assessed multiple times within 72 hours following surgery. Researchers also track time to first rescue analgesic, incidence of complications or adverse events up to 90 days post-surgery, and the duration of hospital stay for about one year. The main outcome measured is overall opioid consumption within 72 hours after surgery, with safety and patient satisfaction also evaluated throughout the study period.

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)